365 related articles for article (PubMed ID: 28668076)
1. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
3. Real-Time Tracking of
Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
Front Immunol; 2018; 9():825. PubMed ID: 29770131
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.
Nham T; Poznanski SM; Fan IY; Vahedi F; Shenouda MM; Lee AJ; Chew MV; Hogg RT; Lee DA; Ashkar AA
J Immunother; 2018; 41(2):64-72. PubMed ID: 29189387
[TBL] [Abstract][Full Text] [Related]
6. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
[TBL] [Abstract][Full Text] [Related]
7. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
9. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
10. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
11. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
Vahedi F; Nham T; Poznanski SM; Chew MV; Shenouda MM; Lee D; Ashkar AA
Sci Rep; 2017 Sep; 7(1):12083. PubMed ID: 28935883
[TBL] [Abstract][Full Text] [Related]
13. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
14.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E; Hallett WH; Murphy WJ
Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells.
Park YK; Shin DJ; Cho D; Kim SK; Lee JJ; Shin MG; Ryang DW; Lee JS; Park MH; Yoon JH; Jegal YJ
Anticancer Res; 2012 Mar; 32(3):839-46. PubMed ID: 22399602
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
Mimura K; Kamiya T; Shiraishi K; Kua LF; Shabbir A; So J; Yong WP; Suzuki Y; Yoshimoto Y; Nakano T; Fujii H; Campana D; Kono K
Int J Cancer; 2014 Sep; 135(6):1390-8. PubMed ID: 24615495
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
